Selvita inks discovery deal with Rottapharm Madaus
Poland-based Selvita is providing drug discovery services to Rottapharm Madaus with the goal of creating a ser of designed and synthesised compounds.
Selvita will apply its drug discovery capabilities, which it also uses for in-house programmes, to the design and synthesis of compounds with therapeutic potential in an indicated area. The compounds, including their optimised synthesis route, will be delivered to Rottapharm Madaus.
Pawel Przewiezlikowski, CEO of Selvita, said: "This project is an immense chance for Selvita to show the great potential of our computational chemistry and chemistry departments.”
Selvita was established in 2007 and employs almost 100 scientists. It is the main shareholder of BioCentrum, a provider of in vitro preclinical ADMET services.
